Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma

被引:182
作者
Gulley, James L. [1 ]
Arlen, Philip M. [1 ]
Tsang, Kwong-Yok [1 ]
Yokokawa, Junko [1 ]
Palena, Claudia [1 ]
Poole, Diane J. [1 ]
Remondo, Cinzia [1 ]
Cereda, Vittore [1 ]
Jones, Jacquin L. [2 ]
Pazdur, Mary P. [1 ]
Higgins, Jack P. [1 ]
Hodge, James W. [1 ]
Steinberg, Seth M. [3 ]
Kotz, Herbert [2 ]
Dahut, William L. [2 ]
Schlom, Jeffrey [1 ]
机构
[1] NCI, Tumor Immunol & Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA
[3] NCI, Biostat & Data Management Sect, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1158/1078-0432.CCR-08-0126
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Poxviral vectors have a proven safety record and can be used to incorporate multiple transgenes. Prior clinical trials with poxviral vaccines have shown that immunologic tolerance to self-antigens can be broken. Carcinoembryonic antigen (CEA) and MUC-1 are overexpressed in a substantial proportion of common solid carcinomas. The primary end point of this study was vaccine safety, with immunologic and clinical responses as secondary end points. Experimental Design: We report here a pilot study of 25 patients treated with a poxviral vaccine regimen consisting of the genes for CEA and MUC-11, along with a triad of costimulatory molecules (TRICOM; composed of B7.1, intercellular adhesion molecule 1, and lymphocyte function - associated antigen 3) engineered into vaccinia (PANVAC-V) as a prime vaccination and into fowlpox (PANVAC-F) as a booster vaccination. Results: The vaccine was well tolerated. Apart from injection-site reaction, no grade >= 2 toxicity was seen in more than 2% of the cycles. Immune responses to MUC-1 and/or CEA were seen following vaccination in 9 of 16 patients tested. A patient with clear cell ovarian cancer and symptomatic ascites had a durable (18-month) clinical response radiographically and biochemically, and one breast cancer patient had a confirmed decrease of >20% in the size of large liver metastasis. Conclusions: This vaccine strategy seems to be safe, is associated with both CD8 and CD4 immune responses, and has shown evidence of clinical activity. Further trials with this agent, either alone or in combination with immunopotentiating and other therapeutic agents, are warranted.
引用
收藏
页码:3060 / 3069
页数:10
相关论文
共 57 条
[1]   Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer [J].
Antonia, SJ ;
Mirza, N ;
Fricke, I ;
Chiappori, A ;
Thompson, P ;
Williams, N ;
Bepler, G ;
Simon, G ;
Janssen, W ;
Lee, JH ;
Menander, K ;
Chada, S ;
Gabrilovich, DI .
CLINICAL CANCER RESEARCH, 2006, 12 (03) :878-887
[2]   The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines [J].
Arlen, P ;
Tsang, KY ;
Marshall, JL ;
Chen, A ;
Steinberg, SM ;
Poole, D ;
Hand, PH ;
Schlom, J ;
Hamilton, JM .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000, 49 (10) :517-529
[3]   A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer [J].
Arlen, PM ;
Gulley, JL ;
Parker, C ;
Skarupa, L ;
Pazdur, M ;
Panicali, D ;
Beetham, P ;
Tsang, KY ;
Grosenbach, DW ;
Feldman, J ;
Steinberg, SM ;
Jones, E ;
Chen, C ;
Marte, J ;
Schlom, J ;
Dahut, W .
CLINICAL CANCER RESEARCH, 2006, 12 (04) :1260-1269
[4]   Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death [J].
Casares, N ;
Pequignot, MO ;
Tesniere, A ;
Ghiringhelli, F ;
Roux, S ;
Chaput, N ;
Schmitt, E ;
Hamai, A ;
Hervas-Stubbs, S ;
Obeid, M ;
Coutant, F ;
Métivier, D ;
Pichard, E ;
Aucouturier, P ;
Pierron, G ;
Garrido, C ;
Zitvogel, L ;
Kroemer, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (12) :1691-1701
[5]   Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy [J].
Chakraborty, M ;
Abrams, SI ;
Camphausen, K ;
Liu, KB ;
Scott, T ;
Coleman, CN ;
Hodge, JW .
JOURNAL OF IMMUNOLOGY, 2003, 170 (12) :6338-6347
[6]   VACCINATION WITH IRRADIATED TUMOR-CELLS ENGINEERED TO SECRETE MURINE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR STIMULATES POTENT, SPECIFIC, AND LONG-LASTING ANTITUMOR IMMUNITY [J].
DRANOFF, G ;
JAFFEE, E ;
LAZENBY, A ;
GOLUMBEK, P ;
LEVITSKY, H ;
BROSE, K ;
JACKSON, V ;
HAMADA, H ;
PARDOLL, D ;
MULLIGAN, RC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (08) :3539-3543
[7]   Pancreatic cancer: a review of recent advances [J].
Eckel, Florian ;
Schneider, Guenter ;
Schmid, Roland M. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (11) :1395-1410
[8]   Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy [J].
Fong, L ;
Hou, YF ;
Rivas, A ;
Benike, C ;
Yuen, A ;
Fisher, GA ;
Davis, MM ;
Engleman, EG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (15) :8809-8814
[9]   Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes [J].
Garnett, CT ;
Palena, C ;
Chakarborty, M ;
Tsang, KY ;
Schlom, J ;
Hodge, JW .
CANCER RESEARCH, 2004, 64 (21) :7985-7994
[10]   Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy [J].
Gribben, JG ;
Ryan, DP ;
Boyajian, R ;
Urban, RG ;
Hedley, ML ;
Beach, K ;
Nealon, P ;
Matulonis, U ;
Campos, S ;
Gilligan, TD ;
Richardson, PG ;
Marshall, B ;
Neuberg, D ;
Nadler, LM .
CLINICAL CANCER RESEARCH, 2005, 11 (12) :4430-4436